Targets › CCKAR
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Aug 2028.
Receptor for cholecystokinin. Mediates pancreatic growth and enzyme secretion, smooth muscle contraction of the gall bladder and stomach. (UniProt, P32238)
Open in Phaseline: the race on CCKAR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City of Hope Medical Center | Gastrin-17 (GAST-17) Gastrin receptor agonist; gut hormone to promote islet cell growth and survival | CCKAR | Phase 1 | Diabetes Mellitus, Type 1 | Aug 2028 |
Diabetes Mellitus, Type 1 (1)
mixed (1)
City of Hope Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.